Literature DB >> 12711473

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.

Nisreen El-Hashemite1, Hongbing Zhang, Elizabeth P Henske, David J Kwiatkowski.   

Abstract

Mutations that inactivate either TSC1 or TSC2 cause tuberous sclerosis. We have used immunoblotting and immunohistochemical analysis to see whether there is phosphorylation of p70 S6 kinase, and the ribosomal S6 protein in angiomyolipomas occurring in tuberous scierosis. Hamartin (encoded by TSC1) and S6K was expressed in all samples. Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas. Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth. We suggest that treatment with rapamycin and its analogues could benefit such patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711473     DOI: 10.1016/S0140-6736(03)13044-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  66 in total

Review 1.  Tuberous sclerosis complex and renal angiomyolipoma: case report and review of the literature.

Authors:  Elisabeth B Winterkorn; Ghaleb H Daouk; Sudha Anupindi; Elizabeth A Thiele
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

Review 2.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

3.  Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target.

Authors:  Nisreen El-Hashemite; David J Kwiatkowski
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-30       Impact factor: 6.914

4.  Coordinated regulation of protein synthesis and degradation by mTORC1.

Authors:  Yinan Zhang; Justin Nicholatos; John R Dreier; Stéphane J H Ricoult; Scott B Widenmaier; Gökhan S Hotamisligil; David J Kwiatkowski; Brendan D Manning
Journal:  Nature       Date:  2014-07-13       Impact factor: 49.962

5.  Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.

Authors:  Stephan Rüegg; Marianna Baybis; Hal Juul; Marc Dichter; Peter B Crino
Journal:  Epilepsy Res       Date:  2007-11-05       Impact factor: 3.045

6.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

Review 7.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.

Authors:  Christopher E Barbieri; Arul M Chinnaiyan; Seth P Lerner; Charles Swanton; Mark A Rubin
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

8.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

9.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

10.  Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.

Authors:  Delia M Talos; David J Kwiatkowski; Kathia Cordero; Peter M Black; Frances E Jensen
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.